Haloperidol Wzf (Haloperidol)

Haloperidol Wzf is indicated for several acute and chronic psychiatric conditions where rapid control of symptoms is required, particularly when oral administration is not feasible.

• Schizophrenia, including acute exacerbations.
• Acute psychotic episodes associated with mood disorders.
• Tourette syndrome with severe motor or vocal tics.
• Severe agitation or aggression that cannot be managed orally.
• Pre‑operative sedation in patients with psychotic disorders.
• Management of delirium in intensive care settings when antipsychotic therapy is needed.

The safety profile of intramuscular haloperidol reflects its pharmacologic activity and includes both frequent and rare adverse events.

Common

• Drowsiness or sedation.
• Extrapyramidal symptoms such as tremor or rigidity.
• Dry mouth and increased salivation.
• Constipation or gastrointestinal discomfort.
• Orthostatic hypotension or dizziness.

Serious

• Neuroleptic malignant syndrome, a life‑threatening reaction.
• Tardive dyskinesia with persistent involuntary movements.
• Severe cardiac arrhythmias, including QT prolongation.
• Significant leukopenia or agranulocytosis.

Clinicians should evaluate patient history and monitor clinical status when prescribing Haloperidol Wzf to minimize risks and ensure appropriate use.

• Assess for cardiovascular disease, as haloperidol may affect heart rhythm.
• Review history of movement disorders; prolonged use can exacerbate extrapyramidal symptoms.
• Use caution in patients with hepatic or renal impairment due to altered drug clearance.
• Monitor for signs of neuroleptic malignant syndrome, especially during dose escalation.
• Evaluate pregnancy and lactation status; safety data are limited.
• Avoid abrupt discontinuation to reduce withdrawal phenomena.

Haloperidol can interact with several medication classes, influencing its efficacy and safety profile.

Avoid

• Other dopamine antagonists or high‑potency antipsychotics, which may increase extrapyramidal risk.
• Medications that prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that raise haloperidol plasma levels.

Use with caution

• CNS depressants including benzodiazepines or opioids, which can enhance sedation.
• Anticholinergic agents that may mask early signs of neuroleptic malignant syndrome.
• Drugs affecting hepatic metabolism like rifampin, which may reduce haloperidol concentrations.